These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21524897)

  • 1. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Kelsoe G; Moody MA; Haynes BF
    Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development.
    Haynes BF; Wiehe K; Alam SM; Weissman D; Saunders KO
    Curr Opin HIV AIDS; 2023 Nov; 18(6):300-308. PubMed ID: 37751363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
    Finney J; Kelsoe G
    Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.
    Pancera M; Changela A; Kwong PD
    Curr Opin HIV AIDS; 2017 May; 12(3):229-240. PubMed ID: 28422787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
    van Schooten J; van Gils MJ
    Retrovirology; 2018 Nov; 15(1):74. PubMed ID: 30477581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
    Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
    PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological mechanisms of inducing HIV immunity in infants.
    Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
    Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing boosting immunogens for HIV-1 vaccine development.
    Liu Q
    Cell Host Microbe; 2024 May; 32(5):632-634. PubMed ID: 38723601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 neutralizing antibodies: understanding nature's pathways.
    Mascola JR; Haynes BF
    Immunol Rev; 2013 Jul; 254(1):225-44. PubMed ID: 23772623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.